ResearchMoz added Latest Research Report titled ” Global Urological Cancer Market to 2022 – Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics ” to it’s Large Report database.
Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered in this report – accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.
A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=759626
Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies – such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.
- Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Disease Cluster Introduction 9
2.2 Symptoms 9
2.3 Etiology and Pathophysiology 10
2.3.1 Etiology 10
2.3.2 Pathophysiology 11
2.4 Co-morbidities and Complications 13
2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 13
2.5.1 Bladder Cancer 14
2.5.2 Kidney Cancer 15
2.5.3 Prostate Cancer 15
2.5.4 Testicular Cancer 16
2.6 Treatment 17
2.6.1 Chemotherapy 17
2.6.2 Surgery and Radiation Therapy 19
2.6.3 Hormonal Therapies 21
2.6.4 Targeted Therapies 22
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/